120 related articles for article (PubMed ID: 11746268)
21. Effects of 1,25-dihydroxyvitamin D3 [1,25(OH)2D3] and its analogues (EB1089 and analog V) on canine adenocarcinoma (CAC-8) in nude mice.
Kunakornsawat S; Rosol TJ; Capen CC; Reddy GS; Binderup L; Inpanbutr N
Biol Pharm Bull; 2002 May; 25(5):642-7. PubMed ID: 12033506
[TBL] [Abstract][Full Text] [Related]
22. Action of low calcemic 1alpha,25-dihydroxyvitamin D3 analogue EB1089 in head and neck squamous cell carcinoma.
Prudencio J; Akutsu N; Benlimame N; Wang T; Bastien Y; Lin R; Black MJ; Alaoui-Jamali MA; White JH
J Natl Cancer Inst; 2001 May; 93(10):745-53. PubMed ID: 11353784
[TBL] [Abstract][Full Text] [Related]
23. pH modulation using CsCl enhances therapeutic effects of vitamin D in LNCaP tumor bearing mice.
Guns ES; Xie X; Fedoruk M; Madera C; Cowell S; Mayer LD; Skov K; Gleave ME; Kozlowski P
Prostate; 2005 Aug; 64(3):316-22. PubMed ID: 15754319
[TBL] [Abstract][Full Text] [Related]
24. A vitamin D analogue (EB1089) inhibits parathyroid hormone-related peptide production and prevents the development of malignancy-associated hypercalcemia in vivo.
Haq M; Kremer R; Goltzman D; Rabbani SA
J Clin Invest; 1993 Jun; 91(6):2416-22. PubMed ID: 8514854
[TBL] [Abstract][Full Text] [Related]
25. Actions of vitamin D3, analogs on human prostate cancer cell lines: comparison with 1,25-dihydroxyvitamin D3.
Skowronski RJ; Peehl DM; Feldman D
Endocrinology; 1995 Jan; 136(1):20-6. PubMed ID: 7530193
[TBL] [Abstract][Full Text] [Related]
26. Decreased growth of established human prostate LNCaP tumors in nude mice fed a low-fat diet.
Wang Y; Corr JG; Thaler HT; Tao Y; Fair WR; Heston WD
J Natl Cancer Inst; 1995 Oct; 87(19):1456-62. PubMed ID: 7545759
[TBL] [Abstract][Full Text] [Related]
27. 1,25-Dihydroxy-16-ene-23-yne-vitamin D3 and prostate cancer cell proliferation in vivo.
Schwartz GG; Hill CC; Oeler TA; Becich MJ; Bahnson RR
Urology; 1995 Sep; 46(3):365-9. PubMed ID: 7660511
[TBL] [Abstract][Full Text] [Related]
28. Suramin-induced decrease in prostate-specific antigen expression with no effect on tumor growth in the LNCaP model of human prostate cancer.
Thalmann GN; Sikes RA; Chang SM; Johnston DA; von Eschenbach AC; Chung LW
J Natl Cancer Inst; 1996 Jun; 88(12):794-801. PubMed ID: 8637045
[TBL] [Abstract][Full Text] [Related]
29. Growth suppression of ovarian cancer xenografts in nude mice by vitamin D analogue EB1089.
Zhang X; Jiang F; Li P; Li C; Ma Q; Nicosia SV; Bai W
Clin Cancer Res; 2005 Jan; 11(1):323-8. PubMed ID: 15671562
[TBL] [Abstract][Full Text] [Related]
30. Assessing the therapeutic and toxicological effects of cesium chloride following administration to nude mice bearing PC-3 or LNCaP prostate cancer xenografts.
Low JC; Wasan KM; Fazli L; Eberding A; Adomat H; Guns ES
Cancer Chemother Pharmacol; 2007 Nov; 60(6):821-9. PubMed ID: 17294190
[TBL] [Abstract][Full Text] [Related]
31. Monomethylated selenium inhibits growth of LNCaP human prostate cancer xenograft accompanied by a decrease in the expression of androgen receptor and prostate-specific antigen (PSA).
Lee SO; Yeon Chun J; Nadiminty N; Trump DL; Ip C; Dong Y; Gao AC
Prostate; 2006 Jul; 66(10):1070-5. PubMed ID: 16637076
[TBL] [Abstract][Full Text] [Related]
32. Antiproliferative effect of 1alpha,25-dihydroxyvitamin D3 in human prostate cancer cell line LNCaP involves reduction of cyclin-dependent kinase 2 activity and persistent G1 accumulation.
Zhuang SH; Burnstein KL
Endocrinology; 1998 Mar; 139(3):1197-207. PubMed ID: 9492054
[TBL] [Abstract][Full Text] [Related]
33. Antitumor activity of mifepristone in the human LNCaP, LNCaP-C4, and LNCaP-C4-2 prostate cancer models in nude mice.
El Etreby MF; Liang Y; Johnson MH; Lewis RW
Prostate; 2000 Feb; 42(2):99-106. PubMed ID: 10617866
[TBL] [Abstract][Full Text] [Related]
34. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo.
Butler LM; Agus DB; Scher HI; Higgins B; Rose A; Cordon-Cardo C; Thaler HT; Rifkind RA; Marks PA; Richon VM
Cancer Res; 2000 Sep; 60(18):5165-70. PubMed ID: 11016644
[TBL] [Abstract][Full Text] [Related]
35. Therapeutic potential of curcumin in human prostate cancer. III. Curcumin inhibits proliferation, induces apoptosis, and inhibits angiogenesis of LNCaP prostate cancer cells in vivo.
Dorai T; Cao YC; Dorai B; Buttyan R; Katz AE
Prostate; 2001 Jun; 47(4):293-303. PubMed ID: 11398177
[TBL] [Abstract][Full Text] [Related]
36. 1,24(S)-dihydroxyvitamin D2, an endogenous vitamin D2 metabolite, inhibits growth of breast cancer cells and tumors.
Zinser GM; Tribble E; Valrance M; Urben CM; Knutson JC; Mazess RB; Strugnell SA; Welsh J
Anticancer Res; 2005; 25(1A):235-41. PubMed ID: 15816543
[TBL] [Abstract][Full Text] [Related]
37. Reversal of hypercalcemia with the vitamin D analogue EB1089 in a human model of squamous cancer.
El Abdaimi K; Papavasiliou V; Rabbani SA; Rhim JS; Goltzman D; Kremer R
Cancer Res; 1999 Jul; 59(14):3325-8. PubMed ID: 10416587
[TBL] [Abstract][Full Text] [Related]
38. Toxicity and antineoplastic effect of (24R)-1,24-dihydroxyvitamin D3 (PRI-2191).
Wietrzyk J; Pełczyńska M; Madej J; Dzimira S; Kuśnierczyk H; Kutner A; Szelejewski W; Opolski A
Steroids; 2004 Sep; 69(10):629-35. PubMed ID: 15465107
[TBL] [Abstract][Full Text] [Related]
39. The effects of 1alpha,24(S)-dihydroxyvitamin D(2) analog on cancer cell proliferation and cytokine expression.
Shany S; Levy Y; Lahav-Cohen M
Steroids; 2001; 66(3-5):319-25. PubMed ID: 11179740
[TBL] [Abstract][Full Text] [Related]
40. A molecular mimic of phosphorylated prolactin markedly reduced tumor incidence and size when DU145 human prostate cancer cells were grown in nude mice.
Xu X; Kreye E; Kuo CB; Walker AM
Cancer Res; 2001 Aug; 61(16):6098-104. PubMed ID: 11507059
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
